Wednesday, July 23, 2025

 

New study finds distinct city-specific gut microbiota linked to diet




BGI Genomics
Distinct City-Specific Gut Microbiota Linked to Diet |BGI Genomics 

image: 

Distinct City-Specific Gut Microbiota Linked to Diet |BGI Genomics

view more 

Credit: BGI Genomics




new study shows that the human gut microbiota can pinpoint whether an adult lives in Wuhan or Shiyan, two cities 500 km apart in China's Hubei Province, with 94 % accuracy. This microbial signature is strongly linked to each city's characteristic diet.

The work is conducted by scientists at BGI Genomics' Institute of Intelligent Medical Research (IIMR) and published in Frontiers in Microbiology this month. Although the groups were matched for age, BMI and smoking status, their intestinal ecosystems diverged in ways that mirror regional lifestyle and dietary preference. The findings of the study further guide precision medicine and raise the prospect of localized precision nutrition and therapeutic strategies.

Geography in the Gut

While previous research has shown that the gut microbiota reflects geographic patterns at the continental and provincial levels, it remains uncertain whether these patterns hold true between neighboring cities within the same province. To investigate this, they applied machine learning to determine whether microbiota data could reliably distinguish between these geographically close populations.

The researchers used shotgun metagenomics to identify 649 bacterial species and 515 metabolic pathways in participants' gut microbiota. Although Wuhan and Shiyan are geographically close, their residents had noticeably different gut bacteria. In Wuhan, people’s microbiota were enriched with Bacteroides stercoris, while in Shiyan, Prevotella copri was more dominant.

There are 12 core bacterial genera, such as Faecalibacterium and Roseburia, were shared by more than 90% of all participants. This suggests a common gut composition across the population. However, the proportions of these bacteria varied depending on where participants lived.

Diet Shapes Microbial Composition

Wuhan sits amid abundant wetlands; freshwater fish, lotus root and leafy greens dominate dinner tables. Shiyan, wedged between Henan, Chongqing and Shaanxi, borrows the wheat-based, chili-laden preferences of its neighbours. These dietary contrasts appear to have etched themselves into the microbiota.

The single strongest predictor of residence in the study's random-forest model, Bacteroides stercoris, was not the core species of the Chinese population but flourished in Wuhan participants. Conversely, Wuhan samples were depleted in Prevotella copri, a species often displaced by Mediterranean-style diets rich in fish and plant foods.

Wuhan's microbiota uniquely harboured the metabolic pathway pyruvate fermentation to isobutanol (PWY-7111)—previously documented in herbivorous bats and in humans consuming plant-forward diets.

Ruminococcus faecis, another Wuhan-enriched driver, has been inversely associated with processed-meat intake, reinforcing the picture of a city that leans on vegetables and fish rather than cured pork.

The researchers also identified 36 bacterial taxa that were significantly more abundant in Wuhan, compared to just 10 in Shiyan. Notably, 63% of these species were location-specific microbiota, which essentially shape the distinct microbial "signatures" of each city.

Testing Utility with Machine Learning

The researchers developed machine-learning models to evaluate the practical utility of their findings. They used a random forest classifier that combined 16 bacterial species and 12 city-specific metabolic pathways. This combined model achieved a high level of accuracy, significantly outperforming models that used only species or only pathways.

The most powerful predictor was Bacteroides stercoris. However, six of the top ten predictors were metabolic pathways. This shows that a microbiota’s function is often more informative than its identity when distinguishing between geographic regions.

Microbiota and Health Markers

Fifteen bacterial species showed correlations with clinical health indicators. For example, Bifidobacterium longum was associated with healthier liver enzyme levels. Flavonifractor plautii was linked to higher low-density lipoprotein (LDL) cholesterol, but only in Wuhan. This indicates that the same bacterial species may affect health differently depending on the local microbial environment. These results offer regional insights in interpreting the relationships between microbiota and health.

"This study challenges the long-standing belief that gut microbiota differences only matter at the scale of continents or provinces," said Professor Li Tao from BGI Genomics' IIMR, corresponding author of the study. "We found that even people living in neighboring cities have distinct microbial patterns."

Furthermore, the study's predictive model is highly accurate, laying the foundation for future precision medicine and personalized health management. The team revealed city-specific microbiota signatures and interaction networks by combining in-depth DNA sequencing with machine-learning tools. These findings help us understand how local environments quietly shape our inner biology, offering a foundation for more personalized healthcare, where diet and treatment could one day be tailored to where you live.

 

About BGI Genomics

BGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.

 

Early detection, smarter treatment: Mapping the next big advances in sepsis research



Faster diagnosis, smarter trials, and targeted therapies could help reduce sepsis deaths and improve global treatment outcomes



Journal of Intensive Medicine

Rethinking Sepsis: Toward Precision, Prediction, and Personalization 

image: 

Sepsis, a leading cause of death worldwide, demands a shift from generalized treatment to personalized, predictive, and technology-enabled strategies to improve outcomes globally

view more 

Credit: Oregon State University from Openverse Image Source Link: https://openverse.org/image/695af320-6d47-4578-9047-3412a0e07b7a?q=sepsis&p=5




Sepsis is a life-threatening condition triggered by a dysregulated host response to infection, leading to organ dysfunction. Accounting for nearly 20% of deaths globally, it remains one of the most critical challenges in global health, especially in resource-limited settings where mortality is disproportionately high. Despite advances in medical care and global efforts like the Surviving Sepsis Campaign, significant gaps persist in how sepsis is detected, managed, and studied.

To help advance sepsis research and care, a special editorial was authored by Dr. Craig Coopersmith, Professor of Surgery and Director of the Emory Critical Care Center, Emory University School of Medicine, USA. The article, titled “Future Directions in Sepsis Research,” provides a comprehensive analysis of the limitations in current sepsis management and outlines priorities for future progress. It advocates for moving beyond broad treatment protocols toward more predictive, personalized, and integrative approaches. The editorial was made available online on April 19, 2025, and was published in Volume 5, Issue 3 of the Journal of Intensive Medicine on July 1, 2025.

One major challenge is the failure to apply existing clinical guidelines effectively at the bedside. Many clinicians are unaware of current protocols or face difficulties implementing them due to low-quality supporting evidence, lack of adaptation to local needs, or inadequate healthcare infrastructure. The editorial underscores the importance of implementation science in narrowing this gap between knowledge and practice. Practical solutions include developing dynamic “living” guidelines, translating them into more languages, tailoring them to region-specific pathogens such as dengue and tuberculosis, and expanding education and support for clinicians in underserved areas.

Improving early prediction is also critical to reducing mortality. Although early antibiotic use improves survival, recognizing infection before it proceeds to sepsis remains difficult. The editorial highlights the potential of artificial intelligence (AI) and machine learning (ML) to fill this gap. “Advanced tools such as AI and ML hold promise for analyzing vast amounts of patient data to detect subtle, early indicators of sepsis that may elude human observation,” he explains. “However, these innovations must overcome significant hurdles, including data privacy concerns, ethical considerations, and the risk of overtreatment due to false positives,” states Dr. Coopersmith.

Diagnostics are another weak link. Traditional methods like blood cultures are slow and unreliable. Although newer rapid diagnostic tools exist, none have become standard practice, and their impact on outcomes remains unclear. At the same time, the specificity of the current Sepsis-3 definition and SOFA score is being questioned, calling for more precise diagnostic frameworks.

On the therapeutic front, antibiotics remain essential, but no treatment has successfully modulated the body’s dysregulated host response. Despite over 100 clinical trials, no immunotherapy has improved survival. A deeper understanding of host-pathogen dynamics, including inflammation, immune suppression, the microbiome, and neural-immune signaling is needed. Multi-omics approaches combined with machine learning may help identify new therapeutic targets.

Traditional clinical trial designs are also under scrutiny. The biological diversity among sepsis patients means a one-size-fits-all model often fails. Personalized strategies based on phenotypes and endotypes, along with adaptive platform trials that can adjust to real-time data, offer more efficient paths to progress.

The article also looks ahead to emerging technologies such as wearable immune monitoring, nanotechnology, and RNA-based therapies that may allow more precise and less toxic interventions. These tools could usher in a future where sepsis care is not only timely, but fully tailored to each patient’s unique biology.

Dr. Coopersmith concludes, “Tackling the global burden of sepsis demands more than new drugs or technologies. It calls for a coordinated, multifaceted approach that integrates timely diagnosis, personalized treatment, equitable implementation, and innovative trial design.”

Grounded in clinical evidence and real-world experience, the editorial outlines both incremental and transformative opportunities to reduce global sepsis mortality—bringing precision medicine in sepsis care closer to reality.

 

***

 

Reference
DOI: https://doi.org/10.1016/j.jointm.2025.03.004

 

 

About Professor Craig M. Coopersmith
Dr. Craig M. Coopersmith is Director of the Emory Critical Care Center and Professor of Surgery at Emory University School of Medicine. He is Principal Investigator or co-Principal Investigator on multiple NIH-funded grants focused on the gut and host response in sepsis, as well as a T32 training grant in critical care. He co-chairs the Surviving Sepsis Campaign and served on the NIH COVID-19 guidelines panel. A past president of the Society of Critical Care Medicine, he has received numerous honors, including the 2023 ACCM Distinguished Investigator Award and Emory’s 2024 Dean’s Distinguished Faculty Lecture and Award.

 

This temporary tattoo could detect an unwanted drug in your drink






American Chemical Society

This temporary tattoo could detect an unwanted drug in your drink 

image: 

This tattoo-like sticker, which can be printed in a variety of designs, detects the presence of a drug often used to “spike” drinks — the letters turn red when exposed to it.

view more 

Credit: Adapted from ACS Sensors 2025, DOI: 10.1021/acssensors.4c03737





Temporary tattoos aren’t just for kids anymore — semi-permanent versions have become a favorite among adults who don’t want the commitment of the real thing. Now, researchers reporting in ACS Sensors have created their own temporary tattoo sticker that has a hidden, but possibly lifesaving, purpose: detecting the presence of one drug used to “spike” alcoholic beverages and facilitate sexual assault. The sticker responds within 1 second to even low concentrations of the drug γ-hydroxybutyrate (GHB).

Unfortunately, consuming a drink spiked with drugs including Rohypnol (commonly known as roofies) or GHB when drinking in a social setting is an ever-present danger — even among friends and acquaintances. These drugs are colorless and tasteless, inducing a stupor in the victim that’s similar to severe alcohol intoxication, which can lead people to being vulnerable to nonconsensual sexual contact or sexual assault. People can protect themselves by testing their drinks with specialized strips or cards that change color when exposed to these drugs. But current tests are often conspicuous or take minutes to report a result, introducing additional danger. So, Gyeong-Ji Kim, Jai Eun An, Kyong-Cheol Ko, Oh Seok Kwon and colleagues wanted to develop a rapid-acting test for GHB that’s worn on the skin using a tattoo-like sticker.

To create the stickers, the researchers placed a mold overtop a thin plastic film decorated with tattoo-like designs. Into the mold, they poured a gel mixture containing a chemical receptor that turns red when it detects GHB. Then they coated the back of the sticker with a diluted glue solution, so it could stick to skin.

The researchers tested the sticker’s ability to detect small amounts of GHB in a variety of beverages: whiskey, vodka, beer, soju (a Korean alcoholic beverage) and coffee. Within a single second, it detected the drug across a range of concentrations and below a level that would induce serious physiological symptoms: 0.01 micrograms of GHB in 1 milliliter of beverage. In practice, a wearer could dip a finger into a beverage, touch the drop to the sticker and see the result almost immediately. And the sticker displays the positive result for up to 30 days after detection, which could be important if it’s needed as a form of evidence of tampering. The researchers say that their sticker technology is inexpensive and easy to manufacture, and it could be commercially available soon.

The authors acknowledge funding from the National Research Foundation of Korea, the Korean National Research Council of Science & Technology, the Ministry of Food and Drug Safety, and the Nanomedical Devices Development Project of the National NanoFab Center.

The paper’s abstract will be available on July 23 at 8 a.m. Eastern time here: http://pubs.acs.org/doi/abs/10.1021/acssensors.4c03737    

###

The American Chemical Society (ACS) is a nonprofit organization founded in 1876 and chartered by the U.S. Congress. ACS is committed to improving all lives through the transforming power of chemistry. Its mission is to advance scientific knowledge, empower a global community and champion scientific integrity, and its vision is a world built on science. The Society is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, e-books and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world’s scientific knowledge. ACS’ main offices are in Washington, D.C., and Columbus, Ohio.

Registered journalists can subscribe to the ACS journalist news portal on EurekAlert! to access embargoed and public science press releases. For media inquiries, contact newsroom@acs.org.

Note: ACS does not conduct research but publishes and publicizes peer-reviewed scientific studies.

Follow us: Facebook | LinkedIn | Instagram

 

Screening for cardiovascular disease marker in community health centers may reduce risk



New American Heart Association initiative, supported by Novartis Pharmaceuticals Corporation, aims to drive awareness, shared decision making around elevated lipoprotein(a), a genetic risk factor for cardiovascular disease



American Heart Association





DALLAS, July 23, 2025 — Elevated lipoprotein(a), also known as Lp(a), is an independent, inherited and causal risk factor for cardiovascular disease, the leading cause of death and disability worldwide.[1] Lp(a) is similar to low-density lipoprotein (LDL), or “bad” cholesterol, yet is caused by genetics and is not impacted by lifestyle modifications.

While it is estimated that 1 in 5 Americans have high Lp(a) levels, many people are not aware of their risk. Research has found less than 1% of people with atherosclerotic cardiovascular disease (ASCVD), which is caused by plaque buildup in the arteries, are tested for Lp(a).[2]

The American Heart Association, a global force changing the future of health for all, has launched the Lp(a) Community Health Centers Discovery Project, supported by Novartis Pharmaceuticals Corporation, to increase awareness about Lp(a). Additionally, the initiative will focus on improving shared decision making between health care professionals and individuals within community health centers (CHCs) on the importance of Lp(a) screening and ASCVD risk management.

“A simple, one-time Lp(a) test can give lifelong insight about overall heart disease risk — especially for people with a family history or who are otherwise at increased risk,” said Kaavya Paruchuri, M.D., American Heart Association volunteer and clinical operations director of the cardiovascular medicine section and director of the Lipid Apheresis Unit, Preventive Cardiology, at Massachusetts General Hospital in Boston. “Community health centers are vital for making this important tool available to more people and helping individuals take control of their heart health.”

Ten CHCs throughout the U.S. signed onto the project in 2024, and 10 additional sites will be added this year. So far, participating CHCs have successfully added new Lp(a) screening processes resulting in increased testing at the sites. This reflects strong momentum for expanding Lp(a) testing access.

Current participating CHCs include:

  • Bay Area Community Health in Fremont, California
  • Bee Busy Wellness Center in Houston
  • Capital Area Health Network in Richmond, Virginia
  • El Centro Family Health in Española, New Mexico
  • Heart of Ohio Family Health Centers in Columbus, Ohio
  • Lone Star Family Health Center in Conroe, Texas
  • Southwest Community Health Center in Bridgeport, Connecticut
  • Spring Branch Community Health Center in Houston
  • The Chautauqua Center in Dunkirk, New York
  • Westside Family Health Center in Culver City, California

In 2023, the American Heart Association launched an initiative called the Lp(a) Discovery Project to improve the number of patients screened for Lp(a) through professional and patient education. This initiative gathered insights from 10 health systems across the country who have established Lp(a) testing processes. Lessons learned from this initiative will be used to drive improvements across CHCs participating in the Lp(a) Discovery Community Health Centers Project.  

Studies have shown that elevated Lp(a) increases risk for ASCVD-related events such as aortic stenosis, heart attack, peripheral artery disease and stroke.[3] Although treatment options for high Lp(a) are limited, some lifestyle changes and medication therapies can assist with lowering a person’s overall risk for heart disease.

A baseline survey conducted as part of the Lp(a) Discovery Project found few U.S. adults are aware of Lp(a), which is accompanied by lack of concern and urgency to have levels checked. U.S. adults are not linking elevated Lp(a) to cardiovascular risk, but when they do, it motivates them to talk to their doctor. Health care professionals are the top source of Lp(a) awareness; their recommendation and personal experience is key to considering getting Lp(a) levels checked.

Community Health Centers can express interest in participating in this initiative by completing the form at heart.org/LpaDiscovery. The deadline is August 15.

Additional Resources:

###

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1. 

 

Smart bacteria could transform global agricultural food production


With the global population expected to reach 10 billion by 2050 and crop yields declining annually, a team of academics from Northumbria University is developing a revolutionary new approach to food security





Northumbria University

From l-r: Dr Angela Sherry, Dr Emma Riley, and Dr Ciaran Kelly, of Northumbria University 

image: 

From l-r: Dr Angela Sherry, Dr Emma Riley, and Dr Ciaran Kelly, of Northumbria University

view more 

Credit: Barry Pells / Northumbria University





With the global population expected to reach 10 billion by 2050 and crop yields declining annually, a team of academics from Northumbria University is developing a revolutionary new approach to food security.

They have been selected by the Advanced Research and Invention Agency (ARIA) as one of only 14 R&D Creators to receive seed funding under its ambitious Programmable Plants opportunity space.

The interdisciplinary team are to receive almost half a million pounds to fund the development of a ‘smart bacterium’ that can dynamically reprogramme how crops respond to environmental stresses in real-time.

The 18-month seed project, entitled Smart Engineered Bacterial Conduits for Enhanced Crop Performance, is led by Dr Ciarán Kelly, Assistant Professor in Synthetic Biology, and Dr Emma Riley, Senior Research Assistant in Biosciences, alongside Dr Angela Sherry, Associate Professor in Microbial Environments, in collaboration with academics from the University of Oxford and University of Leeds.

The project tackles a fundamental challenge in modern agriculture – crops often respond too cautiously to moderate stress conditions such as moderate drought and low nitrate levels in the soil before fertiliser application, which severely impacts their growth.

"Plants have evolved to prioritise survival over yield," explains Dr Kelly. "But this natural survival mechanism is often counter-productive for food production. Even moderate stress causes plants to shut down growth and switch to defence mode, which is a huge limitation when growing crops for human consumption."

The Northumbria team's innovative solution involves engineering bacterial conduits that act as intelligent intermediaries between plants and their environment.

These smart bacteria will sense environmental cues and plant stress signals, then intervene to rebalance plant hormones in real-time, enabling crops to maintain growth under moderate stress conditions.

This technology could unlock the full yield potential of crops while reducing dependence on fertilisers and pesticides.

"Our engineered bacterial conduits will be in constant feedback with the crop, collating signals from the plant and the external environment, and reprogramming plant behaviour through the regulation of key plant-hormone ratios," explains Dr Kelly. "We're introducing rapid, dynamic control of crop behaviour in the field for the first time, reprogramming the plant in real-time to respond quickly and appropriately to stress."

Dr Emma Riley, who brings expertise in plant-bacteria interactions from her PhD research, said: "We're building on decades of research into plant growth-promoting bacteria that are already used safely in agriculture. Our innovation is adding programmable intelligence to these robust systems, allowing dynamic intervention based on real-time stress conditions."

Dr Kelly emphasises the broader implications: "We're not just tweaking existing systems – we're completely reimagining how we approach crop development. Instead of the traditional months-long process of plant genetic modification in laboratories, we're using smart bacteria to transform the plant’s behaviour in the field itself. Being selected by ARIA as one of their R&D Creators highlights the potential global impact of this research and we’re delighted this has been recognised and supported by ARIA.”

ARIA is the UK's newest research funding agency, sponsored by the Department for Science, Innovation and Technology, and funds teams of scientists and engineers to pursue research at the edge of what is scientifically and technologically possible.

ARIA's Programmable Plants opportunity space, led by Programme Director Angie Burnett,      recognises that plants represent 80% of Earth's biomass and are rapidly, cost-effectively and widely distributed across our planet. This makes plants an ideal technological platform to provide low-cost, sustainable resources at scale.               

ARIA's opportunity spaces reach across disciplines, sectors, and institutions, bringing together scientists and engineers with diverse fields of expertise to break down silos and discover new pathways.

Being selected as one of only 14 R&D Creators from a highly competitive field demonstrates the exceptional potential of Northumbria's approach and the team's expertise in synthetic biology, microbiology and plant sciences.

Their 18-month seed project will establish proof-of-concept for the engineered bacterial conduits, with the potential for follow-up funding to develop more sophisticated applications.

The Northumbria team anticipate that the technology could be field-ready within 10-20 years, initially in territories where genetically modified agricultural bacteria are already in use.

Find out more about research at Northumbria University.

 

Watermarks offer no defense against deepfakes



Waterloo researchers create “UnMarker” tool that can remove any AI image watermark, highlighting continuing dangers of deepfakes




University of Waterloo




New research from the University of Waterloo’s Cybersecurity and Privacy Institute demonstrates that any artificial intelligence (AI) image watermark can be removed, without the attacker needing to know the design of the watermark, or even whether an image is watermarked to begin with. 

As AI-generated images and videos became more realistic, citizens and legislators are increasingly concerned about the potential impact of “deepfakes” across politics, the legal system and everyday life. 

“People want a way to verify what’s real and what’s not because the damages will be huge if we can’t,” said Andre Kassis, a PhD candidate in computer science and the lead author on the research. “From political smear campaigns to non-consensual pornography, this technology could have terrible and wide-reaching consequences.”  

AI companies, including OpenAI, Meta, and Google, have offered invisible encoded “watermarks” as a solution, suggesting these secret signatures can allow them to create publicly available tools that consistently and accurately distinguish between AI-generated content and real photos or videos, without revealing the nature of the watermarks. 

The Waterloo team, however, has created a tool, UnMarker, which successfully destroys watermarks without needing to know the specifics of how they’ve been encoded. UnMarker is the first practical and universal tool that can remove watermarking in real-world settings. What sets UnMarker apart is that it requires no knowledge of the watermarking algorithm, no access to internal parameters, and no interaction with the detector at all. It works universally, stripping both traditional and semantic watermarks without any customization.

“While watermarking schemes are typically kept secret by AI companies, they must satisfy two essential properties: they need to be invisible to human users to preserve image quality, and they must be robust, that is, resistant to manipulation of an image like cropping or reducing resolution,” said Dr. Urs Hengartner, associate professor of the David R. Cheriton School of Computer Science at the University of Waterloo. 

“These requirements constrain the possible designs for watermarks significantly. Our key insight is that to meet both criteria, watermarks must operate in the image’s spectral domain, meaning they subtly manipulate how pixel intensities vary across the image.” 

Using a statistical attack, UnMarker looks for places in the image where the pixel frequency is unusual, and then distorts that frequency, making the image unrecognizable to the watermark-recognizing tool but undetectably different to the naked eye. In tests, the method worked more than 50 per cent of the time on different AI models – including Google’s SynthID and Meta’s Stable Signature – without existing knowledge of the images’ origins or watermarking methods. 

“If we can figure this out, so can malicious actors,” Kassis said. “Watermarking is being promoted as this perfect solution, but we’ve shown that this technology is breakable. Deepfakes are still a huge threat. We live in an era where you can’t really trust what you see anymore.”

The research, “UnMarker: A Universal Attack on Defensive Image Watermarking,” appears in the proceedings of the 46th IEEE Symposium on Security and Privacy.